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Abstract
SLIT (sublingual immunotherapy,) induces allergen-specific immune tolerance by sublingual administration of a gradually 
increasing dose of an allergen. The mechanism of SLIT is comparable to those during SCIT (subcutaneous immunotherapy), 
with the exception of local oral dendritic cells, pre-programmed to elicit tolerance. In the SLIT dose, to achieve the same 
efficacy as in SCIT, it should be 50–100 times higher with better safety profile. The highest quality evidence supporting 
the efficacy of SLIT lasting 1 – 3 years has been provided by the large scale double-blind, placebo-controlled (DBPC) trials 
for grass pollen extracts, both in children and adults with allergic rhinitis. Current indications for SLIT are allergic rhinitis 
(and conjunctivitis) in both children and adults sensitized to pollen allergens (trees, grass, Parietaria), house dust mites 
(Dermatophagoides pteronyssinus, Dermatophagoides farinae), cat fur, as well as mild to moderate controlled atopic asthma 
in children sensitized to house dust mites. There are positive findings for both asthma and new sensitization prevention. 
Severe adverse events, including anaphylaxis, are very rare, and no fatalities have been reported. Local adverse reactions 
develop in up to 70 – 80% of patients. Risk factors for SLIT adverse events have not been clearly identified. Risk factors of 
non-adherence to treatment might be dependent on the patient, disease treatment, physician-patient relationship, and 
variables in the health care system organization.
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INTRODUCTION AND OBJECTIVE
SLIT (sublingual immunotherapy,) is a method of inducing 
allergen-specific immune tolerance by sublingual 
administration of a gradually increasing dose of an allergen. 
[1]. SLIT appears to involve some of the pathways that have 
been identified in subcutaneous immunotherapy (SCIT) 
[2]. Considering the favourable safety profile and absence 
of anxiety-provoking injections, SLIT may be preferred in 
children [3, 4]. The aim of this study is to assess the evidence 
supporting the use of SLIT.
The first reports on the use of SLIT appeared in the early 
1970s, hence, experience with SLIT in the treatment of 
allergic diseases is less extensive compared to SCIT [5, 6]. 
Since that time, tremendous progress has been made in 
the methodology of assessing SLIT efficacy, especially with 
respect to the following:
1) randomized double-blind placebo-controlled (DBPC) 
trials – starting from 2004;
2) studies evaluating SLIT efficacy following completion of a 
3-year cycle of vaccinations with a 2-year follow-up [7, 8];
3) meta-analyses and comprehensive reviews spanning the 
period starting from 2004 and ending with the most 
recently published reports on efficacy of treating diverse 
allergic diseases, and on prevention of sensitization to 
various allergens in diverse age groups [7, 9, 10, 11, 12, 
13, 14];
4) studies performed in children, dating back from 1997 to 
the present day [15, 16, 17];
5) practice recommendations on SLIT published in the form 
of national position papers [18, 19].
In most SLIT regimens the allergen preparation is kept 
under the tongue for a few minutes and then swallowed. The 
minority of regimens when the allergen preparation is then 
spat out, will not be considered here. The most commonly 
employed form of vaccine used in SLIT continues to be a 
standardized aqueous allergen solution. In 1998, vaccines in 
the form of sublingual soluble tablets were introduced to the 
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market. Both forms are currently available. The characteristics 
of extracts for sublingual allergen immunotherapy available 
in Poland are presented in Table 1 [20].
Novel forms of treatment – grass monomeric allergoid and 
mite monomeric allergoid in sublingual immunotherapy – are 
under investigation [21, 22] The updated recommendations 
addressing SLIT have been published both by research groups 
in Europe and worldwide [1, 5, 23]. Since 2001, subsequent 
editions of the ARIA guidelines have been updating the 
position on SLIT [24, 25, 26]. Numerous reports emphasize 
the need for a methodological control of research projects 
in order to increase their objectivity [7, 27, 28, 29]. The 
investigations are recommended as being prospective, 
based on double-blind placebo-controlled randomization, 
and their results should be presented in accordance with the 
Consolidated Standards of Reporting Trials (CONSORT) [30].
CURRENT STATE OF KNOWLEDGE
The mechanism of SLIT. The site of allergen application 
plays an important role in the mechanism of tolerance 
induced in the course of SLIT, i.e. oral mucosa, which is 
considered to be ‘immuno-priviledged’[31, 32, 33, 34]. Oral 
mucosa is the ‘entrance gate’ to the gastrointestinal tract, 
where numerous environmental allergens (predominantly 
originating from nutritional proteins, physiological bacterial 
flora and pathogenic microorganisms) come into contact 
with the immune system. Thanks to the potent tolerogenic 
mechanisms of the oral mucosa, inflammatory reactions 
are rare. Various mechanisms of local tolerance have been 
described within the oral mucosa: the absence of MALT 
(mucosa-associated lymphoid tissue) and a small number 
of cells participating in inflammatory reaction (eosinophils, 
mast cells), the presence of lamina propria, which ensures 
limited absorption of antigen macromolecules and contact 
with inflammatory cells situated in the submucosal layer 
[35], the phenomenon of immune exclusion via secretory 
IgA, which restricts antigen penetration [36], the presence 
of IFN-g-producing Th1 lymphocytes [37] and regulatory T 
lymphocytes, which affect immunosupression via intercellular 
mechanisms through cytokine release (IL-10), and the 
induction of anergy or depletion of T lymphocytes [38, 39, 40].
Antigen-presenting cells (APCs), mainly dendritic cells 
(DCs), which are densely distributed in the epithelium, 
lamina propria and submucosal layer of the oral mucosa, are 
crucial for immunotolerance in SLIT. DCs capture antigens 
that reach the oral epithelium (within 15–30 minutes), 
migrate to regional lymph nodes (within the subsequent 12 
– 24 hours) and at the same time transform (by proteolytic 
degradation) antigen proteins into fragments that can be 
presented to T lymphocytes [35, 41]. DCs residing within 
the oral mucosa differ by origin and phenotype:
1) myeloid dendritic cells (mDCs) with the phenotype 
CD11b+/CD11c- and CD11b+/CD11c+ situated in the 
lamina propria and submucosal layer;
2) oral Langerhans cells (oLCs) that express CD1a, CD11b, 
C-type lectin langerin (CD207), receptors for IgE (FcεRI), 
IgG (FcγR)I, FcγRII, FcγRIII and Toll-like receptors 
(TLR)4 – the most numerous in the epithelium and playing 
the key role in antigen capture;
3) plasmocytoid DCs (pDCs) – the least numerous and 
situated in the submucosal layer [42].
For all the DCs subpopulations, in healthy individuals 
as well as in patients undergoing SLIT, there have been 
documented numerous tolerogenic (through the release of 
IL-10 and IL-12) and regulatory functions (through induction 
of differentiation of naive or Th0 lymphocytes into the 
population with the phenotype Th1/Treg [43, 44].
Of critical importance in activating the tolerogenic 
function of DCs and thus SLIT efficacy are:
1) the duration of allergen contact with antigen-presenting 
cells in the oral mucosa;
2) the dose and frequency of allergen contact (application);
3) oral mucosa micro-environment;
4) the effects of adjuvant factors that increase tolerogenic 
abilities and induce a Th1-type response (e.g. MPL – a 
TLR-4 agonist) [31, 45].
Indications for SLIT. Indications for SLIT are aligned with 
general indications for allergen immunotherapy (AIT) 
[46]. Particular indications for SLIT depend on the type of 
hypersensitivity reaction and symptoms, as well as age of 
the patient and clinical condition at the time the therapy 
is initiated.
Qualification for SLIT should be based on assessment of 
clinical, laboratory (immunological) and pharmacological 
Table 1. Characteristics of allergen extracts for SLIT available in Poland 
[20]
Form Dose
Sublingual 
aqueous 
allergen extracts 
(SLIT-drops) –
STALORAL 300 
(Stallergenes, 
France)
IR standardized allergen extract (solvent 50% glycerine 
solution).
Standard extracts: house dust mites (D. pter. 50%, D. farinae 
50%), 5 grass pollens (Dactylis glomerata, Anthoxanthum 
odoratum, Lolium perenne, Poa pratensis, Phleum pretense), 
birch pollen 100%, tree pollens (birch 35%, alder 30%, hazel 
35%), Artemisia vulgaris 100%.
Individual extracts compounds are available.
Initial dose: STALORAL 300 10 IR/ml (1 vial/10 ml) (start 
1 dose on day 1 up to 10 doses on day 6), followed by 
STALORAL 300 100 IR/ml (2 vials/10 ml), 1 dose on day 7, up 
to 8 doses on day 11.
Maintenance dose: STALORAL 300 100 IR/ml (2 vials/10 ml), 8 
doses 3 days per week, or 4 doses every day.
Should be kept under the tongue for 2 minutes after 
application, before being swallowed. Recommended 
treatment: continuation for 3–5 years.
Sublingual 
allergen tablets 
(SLIT-tablet) – 
GRAZAX (ALK/
Abello, Denmark)
Standardized allergen extract of grass pollen from Phleum 
pratense 75,000 SQ-T oral lyophilisate a 30, 60, 90 doses.
Should be kept under the tongue for 1 minute after 
application, no food or drink up to 5 minutes after 
swallowing. Recommended initiation of treatment: at least 4 
months before pollen season.
Sublingual 
allergen tablets 
(SLIT-tablet)
ORALAIR 
(Stallergenes, 
France)
IR standardized 5 grass pollen allergen extract from Dactylis 
glomerata, Anthoxanthum odoratum, Lolium perenne, Poa 
pratensis, Phleum pretense.
100 IR &300 IR– initial dose.
300 IR – maintenance dose.
Initial dose: Oralair 1 tablet/100 IR on day 1, 2 tablets/100 
IR on day 2, followed by Oralair 1 tablet/300 IR on days 3 to 
30 (small blister 3 tablets/100 IR, large blister 28 tablets/300 
IR). Maintenance dose: Oralair 1 tablet/300 IR every day 
(blisters/30 tablets).
Should be kept under the tongue for at least 1 minute (to 
be completely dissolved) after application. Recommended 
initiation of treatment: at least 4 months before pollen 
season.
SLIT – sublingual immunotherapy; SQ-T – Standardized Quality units Tablet; IR – Index of 
Reactivity
45
Annals of Agricultural and Environmental Medicine 2016, Vol 23, No 1
Marek Jutel, Małgorzata Bartkowiak-Emeryk, Anna Bręborowicz, Ewa Cichocka-Jarosz, Andrzej Emeryk, Radosław Gawlik et al. Sublingual immunotherapy (SLIT)…
indications [1, 4, 46]. At all times – and in particular in the 
case of children – the individual profile of the patient and the 
family should be evaluate. The assessment needs to consider 
such factors as risks involved in the very disease and the 
employed therapy, abilities and willingness to adhere to the 
therapy, and psychological determinants.
Immunological indications:
 – Documented IgE-dependent hypersensitivity (as IgE 
presence confirmed in in vivo or in vitro tests) to pollen 
allergens (trees, grass, Parietaria), house dust mites 
(Dermatophagoides pteronyssinus, Dermatophagoides 
farinae) or cat fur [8, 16, 47, 48].
 – It is necessary to confirm the significant clinical importance 
of the above – immunization (see below).
Clinical indications:
 – Significant disease symptoms resulting from exposure to 
the above-mentioned allergens.
 – Disease entities:
1. Allergic rhinitis (and conjunctivitis); anticipated 
effects: alleviation of symptoms, prevention of asthma 
development.
2. Controlled atopic asthma with mild to moderate course; 
anticipated effects: alleviation of asthma symptoms, 
decreased bronchial hypersensitivity.
SLIT is a very good alternative if the patient or the family 
cannot accept injection immunotherapy.
Indications associated with assessment of pharmacological 
efficacy:
1. Lack of anticipated effect,
2. Lack of acceptance of pharmacotherapy on the part of the 
patient or his family (children),
3. Adverse effects after treatment.
NOTE. There are no age-associated indications, yet there 
is limited evidence of efficacy in children below 5 years of 
age [49, 50], only monovalent vaccines have been used in 
controlled studies.
Further studies are necessary to assess SLIT efficacy in 
atopic dermatitis, food allergy and allergy to latex and insect 
venom; current data are not sufficient to recommend SLIT 
in those conditions [51, 52, 53, 54].
Contraindications to SLIT [1, 46]. There are no studies 
focusing on the safety of SLIT when SIT is contraindicated. 
According to expert opinion, it seems reasonable to maintain 
the same contraindications.
 – Absolute:
1. Severe immune systemic disorders, severe circulatory 
system disorders, neoplastic diseases, chronic 
inflammations.
2. Severe asthma – FEV1 less than 70% of the predicted 
normal value in spite of the patient undergoing treatment.
2. β–blocker treatment.
3. Poor adherence and severe mental disturbances.
 – Relative: pregnancy (pre-conception initiated, hitherto 
uncomplicated immunotherapy may possibly be continued; 
initiation of immunotherapy is not recommended).
 – Temporary: inf lammatory processes involving 
gastrointestinal tract mucosa, acute infections, tooth 
extraction, surgery intervention in mouth. Note: a 7-day 
interval prior to and following preventive vaccinations 
must be observed.
Precautions – It is recommended that the first dose of 
SLIT is administered under the supervision of a physician, 
and if tolerated well, followed by home dosing. The patient 
should be educated about the principles of SLIT and the 
requirement of strict adherence to recommendations, and 
be provided with a clear written emergency treatment plan 
in case of adverse effects [2].
Efficacy of SLIT in atopic diseases – criteria of efficacy. 
Based on the position of the European Medicines Agency 
(EMA) Guidelines 2008 (CHMP/EWP/18504/2006), the 
following criteria of efficacy have been adopted for allergen-
specific immunotherapy.
1. A decrease or resolution of allergy symptoms in the first 
season following initiation of AIT. Stable clinical effect in 
the course of AIT (2nd – 3rd year of treatment).
2. Long-term clinical effects maintained after completion 
of treatment and beneficial effects on the natural course 
of the disease.
3. Curing the patient of allergy (symptoms absent for many 
years following treatment, optimally throughout the 
patient’s life).
ALLERGIC RHINITIS
Placebo-controlled clinical trials confirmed significant 
alleviation of clinical symptoms compared to the placebo 
group [9, 55, 56, 57]. Comparing the efficacy of SLIT and SCIT 
is difficult due to an extremely small number of studies that 
would directly compare these two immunotherapy forms [58, 
59, 60, 61]. Of importance are marked differences between 
particular trials, which may also result from the type of 
allergen employed. Based on the available trials, it may be 
surmised that the highest effect of SLIT is demonstrated by 
vaccines containing grass and birch pollen allergens [9, 62].
The normal effect of SCIT is a long-term clinical effect 
maintained after discontinuation of therapy. There are 
only few studies regarding SLIT and to long-term clinical 
effect (after 3 – 5 years of SLIT with grass and house dust 
mites extracts) lasting 1 and 8 years; more will probably 
be published [57, 63]. Three years of treatment with the 
SQ-T (Standardized Quality units Tablet) grass allergy 
immunotherapy resulted in a clinical improvement that 
was sustained 1 year after treatment [57]. SLIT with mites 
extract induced a clinical benefit that persisted for 8 years 
[63]. There are results which confirm disease modification by 
SQ-T grass allergy immunotherapy in addition to effective 
symptomatic treatment of allergic rhinoconjunctivitis [9]. 
The DBPC studies in patients with allergic rhinitis showed 
the impact of SLIT on the natural course of the disease, 
including a decrease in the number of new sensitizations, 
and decreased risk of asthma development
Of particular interest is the efficacy of SLIT in paediatric 
patients. Meta-analyses are available that confirm SLIT 
efficacy [9, 64, 65]; however, depending on the methodology 
employed, some authors caution that no final conclusions 
can be drawn at this time [10].
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Considering the total effect and standardized mean 
difference (SMD), SLIT with house dust mite appears to be 
more effective than SLIT with Parietaria, trees and grass 
pollen. However, the majority of these trials were small, 
with 5 out of 9 trials involving fewer than 20 participants, 
and were highly heterogenous. When comparing the results 
of studies on children with those on adults, standardized 
medication difference (SMD) was statistically significantly 
reduced only in adults [9].
 Studies (n) active (n) placebo SMD p
Adults 26 1,168 1,067 -0.4 <0.00001
Children 12 569 575 -0.16 0.06
Conclusion: SLIT is recommended in the treatment of 
allergic rhinitis in children and adults. SLIT efficacy depends 
on allergen type, maintenance and cumulative dose.
ASTHMA
Assessment of treatment efficacy includes alleviation of 
clinical symptoms, a decreased need for pharmacotherapy 
and improved pulmonary ventilation indices.
In 13 randomized placebo-controlled trials where SLIT 
efficacy in allergic rhinitis and asthma was investigated, 
the duration of treatment was  6 months to 2 years [66]. 
Eleven studies demonstrated alleviation of asthma symptoms, 
while only 2 showed improved spirometry indices (FEV1) 
and decreased bronchial hyperreactivity [66]. An important 
argument for using SLIT in treating patients with asthma 
is the comparison of the SLIT results with the results 
achieved by other methods of asthma treatment. None of 
the studies indicated a decrease in demands for medications 
employed in asthma therapy. Significant improvement was 
also demonstrated in functional pulmonary parameters in 
SLIT-treated vs. budesonide-treated patients in the 5th year 
of treatment [67]. Longitudinal studies on the clinical and 
immunological efficacy of SLIT and natural course of asthma 
are lacking.
A critical assessment was made of 5 meta-analyses, 
emphasizing their drawbacks that might result in over-
interpretation of therapeutic results. These meta-analyses 
were found not to provide sufficiently firm evidence to 
support the use of SLIT in routine asthma therapy [68].
The drawbacks of the studies carried out to-date are as 
follows:
 – considerable heterogeneity of results;
 – the small number of studies performed in large groups 
of patients;
 – little data on the effect of SLIT on pulmonary function.
The recently published meta-analyses that separately 
addressed patients allergic to house dust mites and grass 
pollen indicated clinical improvement only in the patients 
allergic to HDM [13, 14].
CONCLUSION
Even though the findings are promising, the results of SLIT 
still show little effect in meta-analysis; hence, they do not 
provide justification for recommending SLIT in treating all 
asthma patients [66].
ATOPIC DERMATITIS (AD)
At present, there are at our disposal too few studies 
performed on small groups of patients, and the results of 
these investigations are ambiguous. The study carried out 
by Pajno et  al. showed an improvement in the SCORAD 
index solely in individuals allergic to house dust mites 
who suffered from a mild form of AD [69]. In AD patients 
with mono-sensitization to house dust mites, SLIT may be 
considered [70]. The authors of the review emphasize that the 
efficacy of immunotherapy in patients with atopic eczema 
has been poorly investigated in the past 5 years, mostly 
with  small, heterogeneous groups, and short duration of 
study. [53]
Conclusion: Based on the currently available evidence, 
there is no proof of the efficacy of SLIT in patients with AD 
[53].
FOOD ALLERGY
Promising results have been achieved in children allergic 
to cows’ milk and peanuts [51, 52, 71]. The most recent 
and highest quality evidence comes from a randomized, 
double-blind, placebo-controlled multicenter trial, in which 
40 subjects, aged 12 – 37 years (median, 15 years), were 
randomized 1:1 across 5 sites to daily peanut or placebo SLIT. 
After 44 weeks of SLIT, 14 (70%) of 20 subjects receiving 
peanut SLIT were responders, compared with 3 (15%) of 
20 subjects receiving placebo (p <.001). In this rigorous study, 
peanut SLIT safely induced a modest level of desensitization 
in the majority of subjects compared with placebo [71].
CONCLUSION
SLIT in the treatment of food allergy continues to be 
in the clinical trial phase – allergen dose vs. efficacy of 
desensitization. A meta-analysis of studies assessing the 
dependence between SLIT efficacy and allergen dosage 
failed to allow for formulating practical conclusions on 
the recommended allergen content in allergy vaccine and 
optimal desensitization protocols [72]. The data for clear 
dose-dependent effect to the immune modulation have 
been published for sublingual monomeric carbamylated 
mite allergoid [22].
Mode of treatment – continuous and co-seasonal regimen. 
Sustained efficacy of 2- and 4-month pre- and co-seasonal 
treatment with the 300 IR tablet during 3 pollen seasons 
was demonstrated, with reduction in symptoms and rescue 
medication use [73]. In children allergic to grass pollen, both 
protocols were effective compared with placebo, and showed 
similar decreases for combined symptoms/medication score 
and all secondary endpoints, with the exception of nasal 
symptoms that were lower in the pre-co-seasonal group 
[74]. Similar data have been published in a study comparing 
3-year-lasting perennial with co-seasonal grass pollen SLIT 
(drops). The authors showed that the continuous regimen 
performed better than the co-seasonal in the first season, 
whereas in the subsequent years, the two regimens are nearly 
equivalent [75].
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SLIT in polysensitized patients. Most of the studies 
dedicated to SLIT concern monosensitized patients. The 
real life study (POLISMAIL) was designed to evaluate 
current practices in prescribing SLIT in polysensitized 
patients, as well as to evaluate the clinical outcome and 
QoL. Both the severity grade of allergic rhinitis and the 
QoL were significantly improved by 2-year SLIT, indicating 
that SLIT with 1–2 allergen extracts achieves a significant 
improvement in polysensitized patients [76]. In another 
study in polysensitized allergic rhinitis patients, SLIT for 
D. pteronyssinus and/or D. farinae produced improvements 
in both nasal symptoms and rescue medication scores 
comparable to those in monosensitized patients, regardless 
of other positive allergens [77].
SLIT in children. In paediatric sublingual immunotherapy 
efficacy evidence analysis 2009–2012, from 56 articles, 29 met 
an inclusion criteria. New evidence is robust for the pre-, co-
seasonal tablet and drop grass pollen SLIT efficacy in allergic 
rhinitis, and scarce for seasonal asthma. Some evidence for 
Alternaria SLIT efficacy has been published [78]. For house 
dust mite (HDM) SLIT in asthma, there is high-quality 
evidence for medication reduction while maintaining 
symptom control; evidence for HDM SLIT efficacy in 
allergic rhinitis is of moderate-low quality. There is moderate 
evidence for the efficacy of dual grass pollen-HDM SLIT after 
12 months of treatment and 1 year after discontinuation. 
Specific provocation test results (nasal, skin) improved with 
grass pollen and HDM SLIT, while nonspecific bronchial 
provocation results remained unchanged.
Food oral immunotherapy is more promising than food 
SLIT. No anaphylaxis was found among 2469 treated children 
[17] (Tab. 2). Three years of SLIT seems to be an adequate 
duration for the treatment of childhood asthma associated 
with HDM allergy, as 2 further years of SLIT added no 
clinical benefit [79]. Some studies indicate that SLIT in house 
dust mite allergic children should be carried out under the 
supervision of an allergist, as it does not seem to be effective 
in primary care [80].
Safety of SLIT. Reports, meta-analyses and review papers 
indicate a superior safety profile of SLIT, as well as a high 
tolerance of the employed allergen preparations [1, 29, 81, 82, 
83]. Some studies demonstrate that SLIT is safe in children 
under 5 years of age, with a lower limit of 3 years [49, 50] 
and pregnant women [84].
Frequency of SLIT-induced adverse reactions (AE). A 
review of articles on SLIT indicates that severe AE, including 
anaphylaxis, are very rare, and no fatalities have been 
reported to-date. Nevertheless, with increasing numbers of 
patients undergoing treatment, isolated cases of anaphylaxis, 
including anaphylactic shock, generalized urticaria, or 
asthma exacerbation, have been reported [85, 86, 87, 88, 89], 
some of them, however, being questioned [90]. In contrast to 
systemic allergic reactions, local adverse reactions, such as 
pruritus/swelling of mouth, tongue or lips, throat irritation, 
nausea, abdominal pain, vomitus, diarrhea, heartburn or 
uvular oedema, develop frequently in up to 70 – 80% of 
patients [3, 82], the most frequent being oral pruritus (17%), 
throat irritation (14%) and ear pruritus (10%) [91]. Local AEs 
can be early (< 30 minutes) or delayed. Symptoms are graded 
from mild (grade 1) to moderate (grade 2), severe (grade 3), 
and of unknown severity. Several grades of local AEs indicate 
the necessity for discontinuation of the treatment.
Speaking the same language in grading local side-effects 
due to SLIT is important for make comparisons between 
the results of different studies [92]. Local allergic symptoms 
usually persist for a short time only, resolve spontaneously, 
and only in sporadic cases require treatment. They rarely 
lead to discontinuation of therapy; more frequently, they may 
affect its regularity. The adverse effects occur predominantly 
in the initial period of treatment, when allergen doses are 
increased [28]. Risk factors for SLIT AE have not been 
clearly established. From the safety aspect, that SLIT does 
not induce any IgE neosensitization to allergens contained 
in the vaccine, was documented in a cohort of 509 patients 
followed over a 2-year period [93].
Comparison of SLIT vs. SCIT. While comparing sublingual 
and subcutaneous immunotherapy, generalized reactions 
are noted, occurring more frequently in SCIT and local 
reactions in SLIT. Nevertheless, only scarce papers evaluate 
both therapeutic methods together [9, 94]. Pilot randomized 
double-blind, placebo-controlled studies (RDBPC) that 
compared both immunotherapy forms suggest that SCIT 
Table 2. Data of evidence-based studies in children [17]
Duration No. of studies
≤ 6m 6
≤ 12 m 11
12–24m 11
Maintenance dose
<5 ug 4
5–25 ug 8
>25 ug 7
undefined 9
Formulation
Drops 24
Tablets 4
GRADE tool
0 2
1 4
2 6
3 7
4 9
Study participants (n)
< 30 7
30–100 13
over 100 9
SLIT allergens
Grass 11
Tree 3
House dust mites 9
Peanut, milk, mixed 3
Indication, disease
Asthma 5
Rhinitis, rhinoconjunctivitis 22
Food allergy 2
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is superior to SLIT in decreasing symptoms of asthma and 
allergic rhinitis and lower respiratory tract inflammation, 
based on provocation tests, whereas both methods have 
comparable effects on immune parameters (sIgE, IL-10) and 
upper respiratory tract inflammation [58]. Promising results 
have been demonstrated in initial trials combining the 2 
immunotherapy methods, with SCIT as an initial dose (a 
prompt beginning and high potential effect) and SLIT as 
continuation of therapy as a maintenance dose (safety and 
comfort of employment) [95]. The comparison of SLIT vs. SCIT 
in view of available evidence is presented in Table 3 [96, 97, 98].
Non-adherence to treatment. In view of the necessity of daily 
administration of the vaccine over a prolonged time, some 
reports point to possible non-adherence/non-compliance of 
the patients in daily practice. They might be [99, 100, 101, 102]:
1. Patient dependent: presence of physical disorders, cognitive 
difficulties and psychiatric comorbidities, age (children, 
adolescents and elderly present high risk of non-adherence), 
social and family support.
2. Disease dependent: chronicity, symptoms stability or 
absence.
3. Treatment dependent: high number of daily doses taken, 
presence of side-effects, complexity of therapeutic regimes, 
ease of use.
4. Physician-patient relation dependent: poor relationship, 
behavioural inappropriateness by the doctor or patient, 
inadequate patient’s involvement
5. Health care system organization dependent: difficult access 
to health service, high medication costs.
In a trial designed to investigate the adherence aspects 
of SLIT, the adherence rates varied from 75% to more than 
95%. This has been attributed to ease of use, convenience 
and good safety profile [100, 102]. However, data based on 
sales profiles from allergen extracts manufacturers indicated 
that over 50% of patients discontinued SLIT during the first 
year of treatment. The adherence seems to be significantly 
affected by the frequency of following visits, the perception of 
efficacy, and the cost. More detailed education of patients and 
strict follow-up seems to improve the adherence results [100].
CONCLUSIONS AND SUMMARY
SLIT is presently commonly employed in Europe, although 
differences between particular countries are considerable. In 
Poland, aqueous allergen extract and 2 types of sublingual 
allergen tablets (standardized allergen extract of Phleum 
pretense, and 5 grass pollen allergen extract from Dactylis 
glomerata, Anthoxanthum odoratum, Lolium perenne, Poa 
pratensis, Phleum pretense) are available. SLIT, although 
available in Poland, is recommended by physicians to a limited 
extent, which may be associated with the relatively high 
out-of-pocket cost of the therapy for the patients. It should 
be emphasized, however, that pharmaco-economic studies 
carried out in various European countries have demonstrated 
that both SCIT and SLIT may be cost-effective when compared 
with standard treatment over a period of approximately 6 
years [103]. In the western European countries, SLIT with 
Phleum pretense sublingual tablets is a cost-effective strategy 
compared with standard management in the patients with 
rhinoconjunctivitis and co-existing asthma [104].
Current meta-analyses, regardless of the great heterogeneity 
of the studies, are in favour of SLIT in rhinitis in adults 
and asthma and rhinitis in children, although differences 
exist among allergens, with the best results for house dust 
mites and grass pollens [105]; there are also differences in 
results between countries [91]. The clinical efficacy and dose 
dependency have been demonstrated for rhinoconjunctivitis 
due to grass pollen. Reported SLIT allergen dose is a 2.4-fold 
– 92-fold multiplication in comparison to the SCIT dose [2]. 
Safety and efficacy are associated with daily administration of 
an appropriate dose of the medication for a period spanning, 
usually, 2 – 4 years. SLIT appears to be better tolerated 
than SCIT, and systemic side-effects are extremely rare, 
in contrast to frequent local oral side- effects. Although 
safe, SLIT should only be prescribed by an allergy-trained 
physician. SLIT is effective in children aged ≥ 5 years, but may 
be safe in children aged ≥ 3 years of age. The clinical effects 
of SLIT may persist for up to 5 years after discontinuation. 
National and international reports indicate the necessity 
for conducting further clinical trials, especially including a 
direct comparison between SCIT and SLIT with respect to 
efficacy and safety [106, 107, 108, 109, 110].
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UP-DATING COMMENTARY
In view of the fact that the manuscript was accepted for 
publication in October 2013 and published in March 2016, 
the authors consider it necessary to add short comments and 
present the most important conclusions according to studies 
published in the interim.
1. Availability of allergen extracts: At the present time, two 
allergen extracts (Staloral 300 and Oralair manufactured 
by Stallergenes, France) for sublingual immunotherapy 
are unavailable in Europe.
2. SLIT to house dust mites: The III phase trial confirmed the 
efficacy and favourable safety profile of both 6 SQ-HDM 
and 12 SQ-HDM in adults with HDM-induced AR. The 
treatment effect was present from 14 weeks of treatment 
onward [Demoly P, Emminger W, Rehm D, Backer V, 
Tommerup L, Kleine-Tebbe J. Effective treatment of house 
dust mite–induced allergic rhinitis with 2 doses of the SQ 
HDM SLIT-tablet: Results from a randomized, double-
blind, placebo-controlled phase III trial. J Allergy Clin 
Immunol 2016; 137: 444–51]. HDM-sensitized asthmatic 
children treated for at least 3 years with either SCIT or 
SLIT showed sustained clinical improvement. [Karakoc-
Aydiner E, Eifan AO, Baris S, Gunay E, Akturk E, Akkoc T, 
Bahceciler NN, Barlan IB. Long-Term Effect of Sublingual 
and Subcutaneous Immunotherapy in Dust Mite-Allergic 
Children With Asthma/Rhinitis: A 3-Year Prospective 
Randomized Controlled Trial. J Investig Allergol Clin 
Immunol. 2015; 25: 334–42].
3. SLIT in asthma: Lack of data for important outcomes, such 
as exacerbations and quality of life and use of different 
unvalidated symptom and medication scores, limits the 
ability to draw a clinically useful conclusion. Very few 
serious adverse events have been reported, but most studies 
have included patients with intermittent or mild asthma; 
therefore, comment on the safety of SLIT for those with 
moderate or severe asthma is impossible. SLIT is associated 
with increased risk of all adverse events [Normansell R, Kew 
KM, Bridgman AL. Sublingual immunotherapy for asthma. 
Cochrane Database Syst Rev. 2015 Aug 28;8:CD011293].
4. SLIT in atopic dermatitis: The quality of the evidence was 
low mainly due to the differing results between studies, 
lack of blinding in some studies, and relatively few studies 
reporting participant-centred outcome measures. There is 
limited evidence that SIT may be an effective treatment for 
people with atopic eczema [Cochrane Database Syst Rev. 
2016 Feb 12;2:CD008774. Specific allergen immunotherapy 
for the treatment of atopic eczema. Tam H1, Calderon MA, 
Manikam L, Nankervis H, García Núñez I, Williams HC, 
Durham S, Boyle RJ. [Epub ahead of print].
5. SLIT in food allergy: In a long-term study, peanut SLIT 
induced a modest level of desensitization, decreased 
immunologic activity over 3 years in responders, and 
had an excellent long-term safety profile. However, most 
patients discontinued therapy by the end of year 3, and only 
10.8% of subjects achieved sustained unresponsiveness. At 
this time, SLIT for allergy is limited by the low maximum 
dose of food allergen than can be delivered as drops. In the 
future, SLIT for food allergy may be optimized by using 
an alternative delivery vehicle, e.g. dissolvable tablets as 
well as administration in the areas of higher density of 
Langerhans cells, such as vestibular and buccal mucosa 
compared with sublingual mucosa [Burks AW, Wood RA, 
Jones SM, Sicherer SH, Fleischer DM, Scurlock AM, Vickery 
BP, Liu AH, Henning AK, Lindblad R, Dawson P, Plaut 
M, Sampson HA; Consortium of Food Allergy Research. 
Sublingual immunotherapy for peanut allergy: Long-term 
follow-up of a randomized multicenter trial. J Allergy Clin 
Immunol. 2015; 135: 1240–8.e1–3].
6. SLIT in HIV-positive patients: Preliminary data showed that 
SLIT therapy in viro-immunological controlled HAART 
(highly active antiretroviral therapy) treated HIV positive 
patients was efficacious, safe and well tolerated [Iemoli 
E, Borgonovo L, Fusi A, Magni C, Ricci ED, Rizzardini 
G, Piconi S. Sublingual allergen immunotherapy in HIV-
positive patients. Allergy. 2016; 71: 412–5].
7. Quality of SLIT products: For more than half of the 
products, SLIT was not “high dose” as has originally been 
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recommended. When reviewing the low- and high-dose 
products with respect to efficacy in clinical trials included 
in a meta-analysis on SLIT, some low-dose extracts showed 
efficacy [Larenas-Linnemann DE, Mösges R. Dosing of 
European sublingual immunotherapy maintenance solutions 
relative to monthly recommended dosing of subcutaneous 
immunotherapy. Allergy Asthma Proc. 2016; 37: 50–6.]. 
Substantial variations regarding allergen content were 
found among 5 SLIT-HDM products. Therefore, it can 
be necessary to guarantee the quality of the SLIT-HDM 
products and to demonstrate their effectiveness before they 
are marketed [Moreno Benítez F, Espinazo Romeu M, Letrán 
Camacho A, Mas S, García-Cózar FJ, Tabar AI. Variation 
in allergen content in sublingual allergen immunotherapy 
with house dust mites. Allergy. 2015; 70:1413–20].
8. Optimal dosage: The results of a multicentre trial of 
sublingual liquid birch pollen preparation indicate that, 
within the studied dose range, SB 40 000 AUN/ml is the 
most optimal effective and safe dose [Pfaar O, van Twuijver 
E, Boot JD, Opstelten DJ, Klimek L, van Ree R, Diamant Z, 
Kuna P, Panzner P. A randomized DBPC trial to determine 
the optimal effective and safe dose of a SLIT-birch pollen 
extract for the treatment of allergic rhinitis: results of a 
phase II study. Allergy. 2016; 71:99–107].
9. Simultaneous administration of more than one allergen 
extract: In a 4-week sequential SLIT-tablet dosing schedule 
followed by simultaneous intake of timothy grass and 
ragweed tablets was well tolerated [Maloney J, Berman G, 
Gagnon R, Bernstein DI, Nelson HS, Kleine-Tebbe J, Kaur 
A, Li Q, Nolte H. Sequential Treatment Initiation with 
Timothy Grass and Ragweed Sublingual Immunotherapy 
Tablets Followed by Simultaneous Treatment Is Well 
Tolerated. J Allergy Clin Immunol Pract. 2016 Jan 2. pii: 
S2213–2198(15)00647–9. Epub ahead of print].
10. Comparability of SLIT vs SCIT: The comparisons for 
grass pollen immunotherapy products indicate comparable 
reductions in allergic rhinoconjunctivitis symptoms and 
supplemental medication use for SLIT tablets and SCIT in 
the first pollen season [Nelson H, Cartier S, Allen-Ramey 
F, Lawton S, Calderon MA. Network meta-analysis shows 
commercialized subcutaneous and sublingual grass products 
have comparable efficacy. J Allergy Clin Immunol Pract. 2015; 
3: 256–266.e3, Larenas-Linnemann D. Patient selection for 
subcutaneous versus sublingual immunotherapy. Curr Opin 
Allergy Clin Immunol. 2015; 15: 588–95].
11. Side effects and safety aspects: Eosinophilic esophagitis 
as a potential side effect due to SLIT was reported in case 
reports [Miehlke S, Alpan O, Schröder S, Straumann A. 
Induction of eosinophilic esophagitis by sublingual pollen 
immunotherapy. Case Rep Gastroenterol. 2013; 7: 363–8]. 
In-seasonal initiation or switchover of immunotherapy 
with tablet sublingual immunotherapy could potentially 
induce serious adverse reactions, including anaphylaxis 
[Hsiao KC, Smart J. Anaphylaxis caused by in-season 
switchover of sublingual immunotherapy formulation. 
Pediatr Allergy Immunol. 2014; 25: 714–5].
12. A new position paper on sublingual immunotherapy was 
published [Canonica GW1, Cox L, Pawankar R, Baena-
Cagnani CE, Blaiss M, Bonini S, Bousquet J, Calderón 
M, Compalati E, Durham SR, van Wijk RG, Larenas-
Linnemann D, Nelson H, Passalacqua G, Pfaar O, Rosário 
N, Ryan D, Rosenwasser L, Schmid-Grendelmeier P, Senna 
G, Valovirta E, Van Bever H, Vichyanond P, Wahn U, Yusuf 
O. Sublingual immunotherapy: World Allergy Organization 
position paper 2013 update. World Allergy Organ J. 2014; 
7: 6].
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